IP Library Granted Patent US 10,201,518
Granted Patent B2
US 10,201,518 · App. 15/278,916 · Granted Feb 12, 2019

Bismuth(III) compounds and methods thereof

Inventors: Hongzhe Sun (Ap Lei Chau, HK); Richard Yi Tsun Kao (Kowloon, HK); Runming Wang (Hong Kong, HK); Tsz Pui Lai (New Territories, HK); Hongmin Zhang (Aberdeen, HK); Hongyan Li (Ap Lei Chau, HK)
Assignee: THE UNIVERSITY OF HONG KONG
A61K31/28A61K31/407
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,201,518
App. No.
15/278,916
Granted
Feb 12, 2019
Kind
B2
Abstract

The present disclosure relates to a pharmaceutical composition comprising: (a) β-lactam antibiotics and (b) a metallo-β-lactamases (MBLs) inhibitor. The inhibitor relates to Bi(III) compounds or the pharmaceutically acceptable salts thereof. The present patent also provides methods of making Bi(III) compounds or the pharmaceutically acceptable salts thereof. Also provided is a method for treating MBLs-producing bacterial infection using a metal replacement mechanism.

Claims (11)

1. A method to treat a bacterial infection from MBL producing bacteria in a subject, said method comprises administering to the subject: (a) an effective amount of a β-lactam antibiotic; and (b) an effective amount of a Bi(III) compound, or a pharmaceutically acceptable salt thereof, wherein the Bi(III) compound is a complex comprising Bi(III) coordinated to a ligand selected from L5 to L21:

2. The method according to claim 1 , wherein said β-lactam antibiotic is carbapenem.

3. The method according to claim 2 , wherein said carbapenem is meropenem, imipenem, ertapenem, doripenem, biapenem, faropenem, panipenem, razupenem, tebipenem, tomopenem or a combination thereof.

4. The method according to claim 1 , wherein the Bi(III) compound is a metallo-β-lactamase (MBL) inhibitor, said MBL is New-Deli metallo-β-lactamase (NDM), Bacillus cereus metallo-β-lactamase (BCII), Bacteroides fragilis metallo-β-lactamase (CcrA), Imipenemase (IMP), Verona imipenemase (VIM), Dutch. imipenemase (DIM), German imipenemase (GIM), Australia imipenemase (AIM), São Paulo metallo-β-lactamase (SPM) or a combination thereof.

5. The method according to claim 1 , wherein the β-lactam antibiotic and the Bi(III) compound have a molar ratio ranging from 1:16 to 16:1 by weight (w/w).

6. The method according to claim 1 , wherein the β-lactam antibiotic and the Bi(III) compound are present in a mixture or in separate components.

7. The method according to claim 4 , wherein said MBL inhibitor inhibits an MBL through metal replacement of the MBL.

8. The method according to claim 7 , wherein said metal is Zn(II).

9. The method according to claim 7 , wherein said metal replacement is through a substitution of two metal cofactors by one Bi(III) ion.

10. The method according to claim 1 wherein the subject is infected with bacteria that has developed a resistance to carbapenem.

11. The method according to claim 10 wherein the bacteria have developed a resistance to meropenem, imipenem, ertapenem, doripenem, biapenem, faropenem, panipenem, razupenem, tebipenem, tomopenem or a combination thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 28, 2016
From: SUN, HONGZHE; KAO, YI TSUN, RICHARD; WANG, RUNMING; LAI, TSZ PUI; ZHANG, HONGMIN; LI, HONGYAN
To: THE UNIVERSITY OF HONG KONG
Reel/Frame 040787/0116 →
Continuity (1)
Related Publication 20180085335A1 · Mar 29, 2018